The Effect of Palmitoylethanolamide on Pain Intensity, Central and Peripheral Sensitization, and Pain Modulation in Healthy Volunteers—A Randomized, Double-Blinded, Placebo-Controlled Crossover Trial
Randomised controlled trialHumans
- Design
- Randomised controlled trial
- Subjects
- 14 healthy volunteers, in a crossover design
- Dose used in the study
- 400 mg three times a day, against placebo
- Duration
- 4 weeks on each
- What was measured
- Responses to a standard laboratory pain model using repeated heat, plus cold, pressure and heat pain tolerance, wind-up and allodynia, and conditioned pain modulation
What the authors reported
Repeated heat pain fell, cold and heat pain tolerance rose, pressure tolerance and conditioned pain modulation increased, and wind-up and allodynia decreased after palmitoylethanolamide. The authors concluded it acts on both peripheral and central pain mechanisms.
Limits of this study
14 healthy people and experimental pain, not patients with a pain condition. A mechanism study in humans, from the same group that later published the 2023 meta-analysis. It was funded by the City of Graz.
Source
Entry checked against the abstract and citation held by Crossref, the DOI registry on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.